Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943661 | 0.85 | SLC6A4 (0.60) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| SCHEMBL2857779 | 0.85 | SLC6A2 (0.61) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| SCHEMBL6546971 | 0.83 | HTR2A (0.50) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| Ortetamine SCHEMBL4381142 | 0.81 | SLC6A4 (0.70) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| SCHEMBL9468041 | 0.79 | TAAR1 (0.83) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| SCHEMBL27787183 | 0.79 | SLC6A2 (0.54) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| SCHEMBL6547503 | 0.78 | HTR2A (0.46) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| Amphetamine SCHEMBL13746679 | 0.78 | SLC6A2 (1.00) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| Amphetamine SCHEMBL15094242 | 0.78 | SLC6A2 (1.00) | SLC6A4SLC6A2TAAR1MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL8859 | 0.78 | SLC6A2 (1.00) | SLC6A4SLC6A2TAAR1MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102458543-A | Dry powder inhalers | 3M INNOVATIVE PROPERTIES CO | 2012-05-16 | — | — | CN | claimed |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | PHARMAPOTHECA, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | PHARMAPOTHECA, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3478363-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | Chemapotheca LLC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC | 2018-08-30 | — | — | US | disclosed |
| WO-2017147375-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2017-08-31 | — | — | WO | disclosed |
| CN-102271509-A | Novel cyclic benzimidazole derivatives useful anti-diabetic agents | — | 2011-12-07 | — | — | CN | disclosed |
| CN-102272103-A | Isonicotinamide orexin receptor antagonists | — | 2011-12-07 | — | — | CN | disclosed |
| EP-1062511-B1 | IMMUNOASSAYS INVOLVING SURFACE ENHANCED RAMAN SCATTERING | UNIV STRATHCLYDE (GB) | 2009-11-25 | — | — | EP | disclosed |
| CN-101420984-A | Block degradable polymers and conjugates prepared therefrom | NEKTAR THERAPEUTICS AL CORP (US) | 2009-04-29 | — | — | CN | disclosed |
| US-6750065-B1 | FOR USE IN DRUG OR EXPLOSIVE DETECTION | UNIVERSITY OF STRATHCLYDE (GB) | 2004-06-15 | — | — | US | disclosed |
| CN-1441790-A | Enhanced propertied pharmaceuticals | ROHM & HAAS (US) | 2003-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SLC6A4 6/4885SLC6A2 3/4885TAAR1 52/4885 |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | SLC6A4 4/4885SLC6A2 2/4885TAAR1 51/4885 |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | SLC6A3, SLC6A2, CES2 | SLC6A4 4/4885SLC6A2 2/4885TAAR1 40/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | SLC6A4 6/4885SLC6A2 3/4885TAAR1 37/4885 |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | SLC6A3, SLC6A2, CES2 | SLC6A4 4/4885SLC6A2 2/4885TAAR1 51/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SLC6A4 6/4885SLC6A2 3/4885TAAR1 37/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | SLC6A4 6/4885SLC6A2 3/4885TAAR1 52/4885 |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | SLC6A3, CES2, SLC6A2 | SLC6A4 6/4885SLC6A2 3/4885TAAR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.